Skip to main content

Rolph Timothy's Form 4 filing

Akero Therapeutics, Inc.AKRO · filed Apr 28, 2025

Accession no.
0000950170-25-059449
Filed
Apr 28, 2025
Trade date
Apr 24, 2025
Filing delay
4 days
Rule 10b5-1 plan
Checked

This filing lists 2 non-derivative transactions and 2 derivative transactions. Open-market sales total $256.4K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Rolph TimothyCIK 0001779479Officer (Chief Scientific Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Apr 24, 2025Common StockMOption exerciseAcquired+6,250$21.10+$131,875175,971Direct
Apr 24, 2025Common StockSSaleDisposed−6,250$41.03F2−$256,437.5169,721Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Apr 24, 2025Common StockMOption exerciseDisposed−2,566$0.00$026,152Direct
Apr 24, 2025Common StockMOption exerciseDisposed−3,684$0.00$025,389Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.12, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)